Domain Therapeutics, a French and Canadian privately-held biopharmaceutical company, is using transmembrane and G Protein-Coupled Receptor (GPCR) targeting for the discovery and development of innovative therapeutics for the treatment of Central Nervous System (CNS) diseases and cancer.
Using its commercially proven candidate discovery engine (Takeda, Merck Serono and ONO Pharmaceutical), Domain has created a pipeline of high-value projects and partnerships. Validating this approach, two projects discovered by Domain Therapeutics technologies are planned to enter clinical Phase I in early and late 2016.
Domain Therapeutics applies a multi-string corporate strategy to grow its business through:
Domain Therapeutics' business model validated : Lundbeck acquires Prexton Therapeutics for $1.1b
BMS takes license to bioSens-All™ technology
Domain Therapeutics and 5 SATTs Announce an Innovative Commercial and Scientific Partnership to Accelerate Drug Development in FranceLearn more...
Domain Therapeutics will attend the 9th International Meeting on Metabotropic Glutamate Receptors, October 1st -6th in Taormina, Sicily, and co-present with Prexton Therapeutics a poster about the discovery, characterization and anti-parkinsonian effect of a novel mGluR4 PAM chemical series that led to Foliglurax, the first mGluR4 PAM compound in clinical trial